Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease.

Journal of Crohn's & colitis - 1 Dec 2010

Pozler O, Chládek J, Malý J, Hroch M, Dědek P, Beránek M, Krásničanová P

Abstract excerpt

BACKGROUND AND AIM: Azathioprine (AZA) has a slow onset of action in treatment of pediatric inflammatory bowel disease (IBD). It is anticipated, that this delay correlates to the kinetics of 6-thioguanine nucleotides (6-TGN) accumulation. The aim of this study was to evaluate the time to steady state of 6-TGN concentration in red blood cells. METHODS: The inclusion criteria were: a) age 0-19 years b) IBD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azathioprine
Share to Guanine Nucleotides
Share to Immunosuppressive Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inflammatory Bowel Diseases

Share to Mercaptopurine

Share to Methyltransferases

Share to Severity of Illness Index

Share to Thionucleotides

Source

Identifiers

PMID: 21122571
DOI: 10.1016/j.crohns.2010.06.005

Genes

TPMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease.PMID 21122571Read ↗

Population pharmacokinetics of azathioprine active metabolite in patients with inflammatory bowel disease and dosage regimens optimisation.Semantic proximity Read ↗

Deletion of glutathione-s-transferase m1 reduces azathioprine metabolite concentrations in young patients with inflammatory bowel disease.Semantic proximity Read ↗

Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine.Semantic proximity Read ↗

Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy.Semantic proximity Read ↗

Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.Semantic proximity Read ↗

6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.Semantic proximity Read ↗

Non-detectable levels of 6-thioguanine nucleotides and 6-methylmercaptopurine in a patient treated with azathioprine: a case reportSemantic proximity Read ↗

Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine.Semantic proximity Read ↗

Pharmacological monitoring of azathioprine therapy.Semantic proximity Read ↗

Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.Semantic proximity Read ↗

Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.Semantic proximity Read ↗

A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.